Anika Therapeutics, Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Anika Therapeutics reported Q2 2026 revenue of $32.6M (up 16% YoY), with Commercial Channel revenue hitting a record $13.9M (up 17% YoY). The company delivered $3.3M net income and $7.1M adjusted EBITDA (22% margin). Based on strong first-half performance, Anika raised full-year 2026 guidance: total revenue growth to 5%–10% (from 1%–9%), adjusted EBITDA margin to 13%–17% (from 5%–10%). However, 2027 Commercial Channel guidance was cut to 5%–15% growth (from 10%–20%) due to regulatory uncertainty; Hyalofast PMA and Cingal NDA timelines remain uncertain, and the company now excludes unapproved products from forward guidance.
Why this rating
Strong operational turnaround (Q2 profitability, margin expansion, guidance raise) is material for a $147M company; however, regulatory delays on pipeline products and reduced 2027 outlook temper gains. Significant but not transformational.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.